Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
INFUSION, SOLUTION
**Dosage and Administration** As directed by a physician. Dosage rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition and concomitant treatment, and on the patient clinical and laboratory response to treatment. When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear and seal is intact. All injection in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment. Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Sodium Chloride Injection, USP is appropriate. The instructions for use of the medication to be added and other relevant literature must be consulted. After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. For single use only. Discard any unused portion.
INTRAVENOUS
Medical Information
**Indications and Usage** 0.9% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes. 0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.
**Contraindications** None known.
B05XA03
sodium chloride
Manufacturer Information
BAXTER HEALTHCARE (ASIA) PTE LTD
Baxter Healthcare Philppines, Inc.
Active Ingredients
Documents
Package Inserts
Baxter Sodium Chloride Injection USP 0.9% PI.pdf
Approved: September 14, 2022